A highly potent, orally bioavailable pyrazole-derived cannabinoid CB2 receptor-selective full agonist for in vivo studies
A. Chicca, D. Batora, C. Ullmer, A. Caruso, J. Fingerle, T. Hartung, R. Degen, M. Mueller, U. Grether, P. Pacher, J. Gertsch
This paper develops and characterizes RNB-61, a potent and selective CB2R agonist with favorable pharmacokinetics, showing nephroprotective effects in kidney injury models.
bioRxiv · Apr 26, 2024 · PreprintPharmacology & Toxicology